For example, targeting the FGFR3/MYC loop with either JQ1 or inhibitors of FGFR3, P38 or AKT has shown promising therapeutic potential in BLCA patients with aberrant FGFR3 activation [50]. This evidence concerns the gene AKT1 and bladder transitional cell carcinoma.